
|Videos|April 25, 2014
PD-L1 Expression in Non-Clear Cell Renal Cell Cancer
Author(s)David F. McDermott, MD
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
Advertisement
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
Clinical Pearls:
- In the past, it was thought that immune therapies worked better in clear-cell kidney cancer compared to non-clear cell kidney cancer
- A study found that non-clear cell tumors expressed PD-L1 on their tumor surface, begging the question if these patients might respond to PD-1 or PD-L1 antibodies
- Patients with non-clear cell tumors should be included in future trials that include PD-1 or PD-L1 antibodies
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
5































